Endece

Executive Summary

Endece is a private, preclinical-stage biopharmaceutical company headquartered in Cambridge, USA, founded in 2018. The company is dedicated to developing novel small molecule therapeutics for neurodegenerative diseases, with a primary focus on promoting remyelination and preventing demyelination in the central nervous system. Its lead asset, NDC-1308, is a dual-action molecule designed to simultaneously induce remyelination and inhibit demyelination, targeting diseases such as multiple sclerosis (MS) and other demyelinating disorders. Endece's approach is differentiated by its focus on small molecules, which offer advantages in terms of oral bioavailability, blood-brain barrier penetration, and manufacturing scalability compared to biologics. The company operates at the preclinical stage, with no disclosed financing rounds or valuation, indicating an early and possibly capital-efficient development phase. Endece's therapeutic strategy addresses a significant unmet need in neurodegenerative diseases, where current treatments primarily modulate the immune system but do not effectively promote repair of damaged myelin. If successful, NDC-1308 could become a first-in-class remyelinating therapy, potentially transforming the standard of care for MS. However, as a preclinical-stage company with no publicly available data, Endece faces high technical and regulatory risk. The need for robust proof-of-concept in animal models and subsequent early-phase clinical trials represents substantial milestones. Conviction score is moderate, reflecting the attractive therapeutic hypothesis tempered by the early stage and lack of validated clinical data.

Upcoming Catalysts (preview)

• Q4 2026NDC-1308 preclinical efficacy data release60% success
• Q2 2027IND filing for NDC-130840% success
• Q4 2026Strategic partnership or licensing deal for NDC-130830% success